Industrial Fermentation and Strain Improvement of ... · PDF fileprocess definition...
Transcript of Industrial Fermentation and Strain Improvement of ... · PDF fileprocess definition...
Dipartimento di Biotecnologie e Scienze della Vita Università degli Studi dell’Insubria Varese
Interuniversitary Research Center of Protein Biotechnology “The Protein Factory”,
Politecnico of Milano and University of Insubria
Industrial Fermentation and Strain Improvement of
Producing Microorganisms
Flavia MarinelliFlavia Marinelli
Dubrovnik Summer School 31-8-2012
ExtractBankExtractBank
HTS
Strain Collection
Strain Collection
Enviromental samples
Selected strains
Flask fermentationMicrobial population
AssayAssay
TargetTarget
Optimized LeadOptimized Lead
TargetTarget
AssayAssay
Extract BankExtract Bank
HITHIT
LeadLead
Screening
Strain CollectionStrain Collection
Biological & ChemicalProfiling, Patent
Clinical candidateClinical candidate
Supply by fermentationIn vivo efficacy, PK, Tox
Strain taxonomyand maintenance
Vegetative and fermentation medium optimization
Isolation of spontaneous
mutants & strain purification
Fermentationprocessdefinition
Mutagenesisand selection
ProcessScale-up
Recombination byprotoplast fusion
Metabolic engineering
Strain maintenance
Filamentous actinomycetes and fungi survive aslyophilized for 25 years (MCB)
Good viability and stability at – 80°C (WCB)
Myxobacteria very often do not survive aslyophilized and/or cryopreserved
Cyanobacteria have specific requests of light and air bubling and have to be subcloned each month
Fingerprinting of the producing organism and quality of culture collection
Identity, stability, vitality, reproducibility,
safety and security
Patent, IPR protection, compliance with the regulatoryauthorities, drug master files, FDA approval etc.
Concept of Working Cell Bank and Master Cell Bank
Strain taxonomyand maintenance
Vegetative and fermentation medium optimization
Isolation of spontaneous
mutants & strain purification
Fermentationprocessdefinition
Mutagenesisand selection
ProcessScale-up
Recombination byprotoplast fusion
Metabolic engineering
First Screening of Culture Collection Strains and Literature Media
First Screening of Culture Collection Strains and Literature Media
Black box model of cell metabolism: “secondary metabolite" producers are generally
chemoorganotrophes
- One by one change
- Experimental design with the help of statisticalsoftwares
- Biochemical methods: precursors or effectors
Methods to optimize medium composition in fermentation processes
Methods to optimize medium composition in fermentation processes
Simplified Plackett-Burman factorial design experiments: the set up and data analysis was performed using Statgraphics plus 4.1 software
(Statistical Graphics Corp, Herndon, USA)
Volontè, Protein Expression and Purification, 2008
E26 [ g / l ]Yeast autolisate 4NaCl 1.25SBM 20Dextrose 25CaCO3 (B) 5Antifoam (Hodag) 0.3H2O demi
WCB -80°C Reactivation
cultureE26
1 % (v/v)
Vegetative seed
E26
3 % (v/v)
72-96h, 28°C, 200 rpm
Production,
AF3
10 % (v/v)
72-96 h, 28°C
g/L AF3Dextrose 11Sucrose 10Malt extract 25Yeast autolysate 12SBM 30NaCl 0,3Valine 1CaCO3 -Antifoam (Hodag) 0,3H2O demi
BATCH o FED-BATCH fermentationprocess to produce an antibiotic from an
actinomycete FeedingGlucose and precursors
SIROLIMUSChemical structure C51H79NO13
Molecular Weight 914.172 g/mol
Synonyms Rapamycine
Brand Names Rapamune
Producing strains S. hygroscopicus
Clinical Uses
Sirolimus in transplantation
• Kidney
Sirolimus non-transplantation uses
• Anti cancer activity (kidney, brain)
• Antifungal agent
• Starting compound for derivatives
Uni
vers
ity o
f Ins
ubria
-D
BM
S
May 2007 - Temsirolimus (trade name Torisel ® - Wyeth Pharmaceutical) was approved bythe US FDA for the treatment of of patients with advanced kidney cancer.
March 2009 - Everolimus (trade name Afinitor ® - Novartis) was approved by the US FDA for the treatment of patients with advanced kidney cancer.
Uni
vers
ity o
f Ins
ubria
-D
BM
SIncrease in Sirolimus production
SIROLIMUS FERMENTATION PROCESS
0
20
40
60
80
100
120
140
160
180
Yiel
d (m
g/L)
C.Taurino et al. unpublished results
Free pHpH control at 4.3 + glucose feeding 10 g/(L d)
Free pH pH controlPMVpO2
pH controlledfed-batchfermentationtime course
Precursors & effectors:
Phenyl acetic acid in Penicillin G Phenoxy acetic acid in Penicillin VAminoacids in peptide antibioticsFatty acids or their aminoacidic precusors in lipopeptidessuch as teicoplanin, A40926 and ramoplaninPropanol in erythromycin and spinosynMethionine in cephalosporinBenzyl thiocyanate in tetracyclineDiethylbarbituric acid in rifamycin
Glycopeptide AntibioticTeicoplanin active against
multiresistant gram positive infections
5 µm
Actinoplanesteichomyceticus
Teicoplanin TA2 complex
Targosid:T-A2-1, T-A2-2, T-A2-3, T-A2-4 and T-A 2-5 represent6, 58.3, 7.3, 14.4 and 14 % of the total T-A2
Minutes
0 2 4 6 8 10 12 14 16 18 20 22 24
mAU
-2
0
2
4
6
8
10
12
14
16
18
20
22
24
mAU
-2
0
2
4
6
8
10
12
14
16
18
20
22
24
DAD-CH1 254 nmstandard teico 250mg-lstandard teico 250mg-l.dat
TA2-1
T-A2-2
T-A2-3
T-A2-4T-A2-5
Targosid250mg/L
European Pharmacopoeia
Growth and teicoplanin production in 3 L-batch fermentations of A. teichomyceticus ATCC 31121 in TM1
The pH value was naturally self-regulated, whereas the pO2 was controlled over the 20% of saturation by adjusting agitation speed.
In (A), time courses of pH (●, solid line), pO2 (□, dashed line), glucose (▲, solid line), and growth curve measured as dry weight (Δ, dashed line) and PMV (■, solid line). In (B), production of T-A2 measured by HPLC analysis as mg/L (filled bars).
C.Taurino et al. Microbial Cell Factories 2011
HPLC profile of 120 hour sample showing the following complex composition:
T-A2-1, T-A2-2, T-A2-3, T-A2-4 and T-A 2-5represent 7.3, 60.2, 13.1, 9.1 and 10.3 %of the total T-A2
Control fermentation
2.5 g/L corn oil
2.5 g/L olive oil
2.5 g/L sesame
oil
β -oxidation
Oleic acid C18H34O2Oleic acid C18H34O2 T-A2-3
n C:10:0
T-A2-3
n C:10:0
β -oxidation
Linoleic acid C18H32O2Linoleic acid C18H32O2 T-A2-1
n C:10:1
T-A2-1
n C:10:1
I. Biosynthetic tool : addition of fatty acid as precursors of linear acyl moieties in teicoplanin complex
T-A2-2T-A2-2
T-A2-4
T-A2-5T-A2-5
II. Biosynthetic tool : addition of amino acids as precursors of branched acyl moieties in teicoplanin complex
iso C:10:0
anteiso C:11:0
iso C:11:0
Growth and teicoplanin production in 3 L-batch fermentations of A. teichomyceticus ATCC 31121 in TM1
added with L-valine
The pH value was naturally self-regulated, whereas the pO2 was controlled over the 20% of saturation by adjusting agitation speed.
In (A), time courses of pH (●, solid line), pO2 (□, dashed line), glucose (▲, solid line), and growth curve measured as dry weight (Δ, dashed line) and PMV (■, solid line). In (B), production of T-A2 measured by HPLC analysis as mg/L (filled bars).
C.Taurino et al. Microbial Cell Factories 2011
HPLC profile of 120 hour sample showing the following complex composition:
T-A2-1, T-A2-2, T-A2-3, T-A2-4 and T-A2-5represent 7.3, 73.4 ,10.5 ,2.0 and 6.8 % of the
total T-A2.
Addition of L-valine increases T-A2-2and total productivity
Addition of L-valine increases T-A2-2and total productivity
CombinationCombination of oil and of oil and LL--valinevaline effecteffecttoto modulate modulate complexcomplex compositioncomposition
Control
Corn oil 2,5 g/L
Corn oil 2,5 g/L + L-Val 1 g/L
Minutes
8,5 9,0 9,5 10,0 10,5 11,0 11,5 12,0 12,5 13,0 13,5 14,0 14,5 15,0 15,5 16,0 16,5
0
50
100
0
50
100
mAU
150
200
250
mA
U
150
200
250250
300
350
400
450
250
300
350
400
450DAD-CH1 236 nmWT controllo1 144h 22-07-10WT controllo1 144h 22-07-10
DAD-CH1 236 nmWT + Corn oil 2,5gL 22-07-10WT + Corn oil 2,5gL 22-07-10
DAD-CH1 236 nmWT + Corn oil 2,5gL + Val 1gLWT + Corn oil 2,5gL + Val 1gL
C.Taurino et al. Microbial Cell Factories 2011
Elicitors:
Heavy metals
Rare earth elements(17 elements including scandium, yttrium and lanthanides)
Oils
Microbial cell wall components
Dimethylsulfoxide
S-Adenosylmethionine
N-acetylglucosamine
On-line and off-line analyses: analytical tools are extremely
important for the “metabolome” and for the flux analysis